Download Image
    
Share
  
Post
AER002 for COVID-19
1 study with 36 patients
No significant improvements are seen in meta analysis to date.
COVID-19 AER002 studies. Dec 2025. c19early.org
0 0.5 1 1.5+ All studies -6% RCTs -6% Late -6% FavorsAER002 Favorscontrol
Oct 28
 Peluso et al., NCT05877508 An Exploratory, Randomized, Double-Blind Placebo-Controlled Study to Assess the Safety of an Anti-SARS-CoV-2 Monoclonal Antibody and Response to Treatment in Individuals With Long COVID (outSMART-LC)
6% higher long COVID (p=0.25). RCT 36 patients showing no improvement in long COVID with AER002.